Findings by Färkkilä et al.47 demonstrated that spatial proximity between PD-1+ TILs with PD-L1+ myeloid cells was associated with improved response to niraparib and pembrolizumab in patients with ovarian cancer. This evidence concerns the gene CD274 and ovarian cancer.